课件：心脏性猝死的一级预防.ppt

* * Focusing on cardiac arrest survivors is NOT the answer because these patients represent only a very small percentage of the total number of patients who experience SCA each year. To address the greatest number of patients, primary prevention therapies will be required. Today, we can effectively identify/treat a very small portion of the total number of patients who experience SCA. SCD-HeFT may siginficantly increase our ability to treat high-risk heart failure patients. * * These results come from the MADIT-II study. Mortality risk in contemporary post- MI pts with EF 30% tends to increase as a function of time from last MI. Correspondingly, survival benefit from the ICD increases significantly with time, up to 15 years following MI. Mortality risk in contemporary post- MI pts with EF 30% tends to increase as a function of time from last MI. These results show the mortality results for each time period studied. They are not cumulative mortality rates. MADIT-II showed that a patient’s risk for SCA increased with time. * 225,000 to 300,000 of SCA patients in the U.S. have had a previous MI. * * The proportionate contribution of SCD to total mortality in HF associated with reduced left ventricular function has not changed substantially between the Framingham data and now. Kannel WB, Wilson PWF, DAgostino RB, Cobb J. Sudden coronary death in women. Am Heart J 1998 Aug; 136: 205-212 * * * * ICD therapy reduced overall mortality by 54% compared to conventional therapy (relative risk reduction). * 20 MUSTT was the next major primary prevention study that showed excellent results with ICD therapy. MUSTT was originally intended to compare EP-guided therapy (ICD or AAD) versus no antiarrhythmic therapy. On further analysis, the investigators found that ICD therapy was far superior to AAD drug therapy. The primary endpoint of MUSTT was arrhythmic mortality unlike all the other ICD trials which used overall mortality as the primary endpoint. The secondar